Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 5, Issue 11

June 8 2021

In this Issue

STIMULUS REPORT
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
COMMENTARIES
ERRATA

STIMULUS REPORT

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Clinical Trials & Observations

Francis A. Ayuk,Carolina Berger,Anita Badbaran,Tatjana Zabelina,Tanja Sonntag,Kristoffer Riecken,Maria Geffken,Dominic Wichmann,Christian Frenzel,Guenther Thayssen,Silke Zeschke,Nicolaus Kröger,Boris Fehse

View Articletitled, Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD

Toshihito Hirai,Po-Yu Lin,Federico Simonetta,Kristina Maas-Bauer,Mustafa Turkoz,Melissa Mavers,Jeanette Baker,Robert S. Negrin

View Articletitled, Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD

Supplemental data

LYMPHOID NEOPLASIA

Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring

Fei Qi,Zheng Cao,Bo Chen,Yue Chai,Jing Lin,Junyi Ye,Yuce Wei,Hao Liu,Han Han-Zhang,Xinru Mao,Xiaoli Feng,Mei Dong

View Articletitled, Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring

Supplemental data

MYELOID NEOPLASIA

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Damodaran Narayanan,Olga Pozdnyakova,Robert P. Hasserjian,Sanjay S. Patel,Olga K. Weinberg

View Articletitled, Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Supplemental data

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia

Emma M. Carrington,Cynthia Louis,Tobias Kratina,Manuela Hancock,Christine R. Keenan,Nadia Iannarella,Rhys S. Allan,Ahmad Z. Wardak,Peter E. Czabotar,Marco J. Herold,Robyn L. Schenk,Christine A. White,Damian D’Silva,Yuyan Yang,Wesley Wong,Huon Wong,Vanessa L. Bryant,Nicholas D. Huntington,Jai Rautela,Robyn M. Sutherland,Yifan Zhan,Jacinta Hansen,Duong Nhu,Guillaume Lessene,Ian P. Wicks,Andrew M. Lew

View Articletitled, BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia

Supplemental data

COMMENTARIES

Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?
Clinical Trials & Observations

Anders Erik Astrup Dahm,Per Morten Sandset

View Articletitled, Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers
Clinical Trials & Observations

Sophie Paczesny,Marcelo C. Pasquini,Steven Z. Pavletic,Amit Agarwal,Stephen Spellman,Leslie Kean,Chantale Bernatchez,Juliane Gust,Verena Staedtke,Miguel-Angel Perales

View Articletitled, Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers

Supplemental data

ERRATA

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1⁻ MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

View Articletitled, Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.

View Articletitled, Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.

Front Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Time to revisit reduced-dose radiotherapy for PCNSL?

Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.

Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Table of Contents

STIMULUS REPORT

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD

LYMPHOID NEOPLASIA

Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring

MYELOID NEOPLASIA

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia

COMMENTARIES

Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?
Clinical Trials & Observations

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers
Clinical Trials & Observations

ERRATA

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1⁻ MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

STIMULUS REPORT

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting Clinical Trials & Observations

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD

LYMPHOID NEOPLASIA

Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring

MYELOID NEOPLASIA

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia

COMMENTARIES

Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences? Clinical Trials & Observations

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers Clinical Trials & Observations

ERRATA

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.

Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Clinical Trials & Observations

Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?
Clinical Trials & Observations

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers
Clinical Trials & Observations

Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1⁻ MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748-4757.